Applying Evidence-Based Therapy Through Oncology Nursing That Maximizes HER2-Targeted Efficacy While Enhancing Tolerability

Applying Evidence-Based Therapy Through Oncology Nursing That Maximizes HER2-Targeted Efficacy While Enhancing Tolerability is organized by Med Learning Group.

Program Overview:
Oncology nurses are in an inherently valuable position to be in the frontline for treatment of HER2-positive solid tumors. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience. For additional resources, please visit www.oncologynurse-ce.com.

Learning Objectives:
• Evaluate the role that human epidermal growth factor receptor plays in the tumorigenesis and prognosis of patients with HER2-positive solid tumors.
• Summarize the efficacy and safety data of both HER2-targeted ADCs and kinase inhibitors in the 2nd line treatment of patients with HER2-positive solid tumors
• Discuss best practices for the safe intravenous administration of ADC therapy and monitoring for adverse events in patients with HER2-positive advanced disease beyond the first-line
• Appreciate the essential role the oncology nurse plays in patient education and management of treatment-related adverse events of HER2-directed therapy